Market research
23E2.F Ekso Bionics Holdings, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.89
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- Not available
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.89
About
About Ekso Bionics Holdings, Inc
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 23E2.F discussion.
5 years, 5 months ago
Ekso Bionics Holdings, Inc is currently in a long term downtrend where the price is trading 20.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Ekso Bionics Holdings, Inc's total revenue sank by 39.4% to $2M since the same quarter in the previous year.
Its net income has dropped by 46.1% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 16.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Ekso Bionics Holdings, Inc gets an overall score of 1/5.